Our Pricing

Wegovy Weight Loss Results: What Clinical Trials Show

Published on: June 03, 2026

Understanding wegovy weight loss results clinical trials helps UK patients set realistic expectations before starting treatment. Clinical evidence from the landmark STEP trials demonstrates that adults taking Wegovy (semaglutide 2.4mg) achieved an average 15% body weight reduction over 68 weeks, significantly outperforming placebo groups [1]. At Cured Pharmacy, our UK-registered clinical team assesses every patient individually to determine if Wegovy is suitable for your weight loss goals.

STEP Trial Programme: The Foundation of Wegovy Weight Loss Results Clinical Trials

The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial programme represents the most comprehensive evaluation of semaglutide 2.4mg for weight management ever conducted. Across five major trials involving over 4,500 participants, researchers examined Wegovy's efficacy in diverse patient populations including those with type 2 diabetes, cardiovascular conditions, and obesity alone [1][2].

In STEP 1, the pivotal 68-week trial of 1,961 adults without diabetes, participants receiving Wegovy achieved an average weight loss of 15.3kg (approximately 15% of initial body weight) compared to 2.6kg in the placebo group [1]. Nearly one-third of Wegovy participants lost 20% or more of their starting weight, a threshold rarely seen with previous pharmaceutical interventions.

STEP 2 specifically examined patients with type 2 diabetes, demonstrating that Wegovy produced an average 9.6% weight reduction over 68 weeks alongside improved glycaemic control [2]. This dual benefit makes semaglutide particularly valuable for UK patients managing both obesity and diabetes, subject to prescriber assessment.

Timeline of Wegovy Weight Loss Results: What to Expect Month by Month

Clinical trial data reveals a predictable pattern of weight reduction with Wegovy, though individual results vary based on adherence, lifestyle factors, and baseline characteristics. During the initial dose escalation phase (weeks 0-16), patients typically experience modest weight loss of 5-7% as the dose gradually increases from 0.25mg to the maintenance dose of 2.4mg weekly [1].

The most substantial weight loss occurs between weeks 16 and 52, with trial participants losing an additional 8-10% of their initial body weight during this period. Weight reduction continues at a slower rate through week 68, after which most patients achieve a stable plateau [1][3].

At Cured Pharmacy, our superintendent pharmacist Tarun Kumar emphasises that maintaining weight loss requires ongoing treatment and lifestyle modifications. The STEP 4 withdrawal trial demonstrated that patients who discontinued Wegovy after 20 weeks regained approximately two-thirds of their lost weight within the following year, whilst those who continued treatment maintained their results [3].

Factors Influencing Individual Wegovy Weight Loss Results

Whilst clinical trials provide average outcomes, individual responses to Wegovy vary considerably. Trial data shows that approximately 86% of participants lost at least 5% of their body weight, 69% lost at least 10%, and 50% lost at least 15% [1]. Factors associated with greater weight loss include higher baseline BMI, younger age, and adherence to dietary modifications alongside medication.

UK prescribers at Cured Pharmacy assess your complete medical history, current medications, and weight loss goals during the online consultation to determine if Wegovy is appropriate for you. All prescription treatments require clinical approval by a UK-registered prescriber before dispensing.

Wegovy Clinical Trial Results Compared to Other Weight Loss Treatments

When evaluating wegovy clinical trial results uk data against alternative treatments, semaglutide 2.4mg demonstrates superior efficacy compared to earlier GLP-1 receptor agonists. Liraglutide 3.0mg (marketed as Saxenda), the previous standard for injectable weight loss medication, produced an average 8% weight reduction over 56 weeks in the SCALE trials—approximately half the effect observed with Wegovy [4].

Oral medications licensed for weight management in the UK, including orlistat and naltrexone/bupropion combinations, typically produce 5-7% average weight loss in clinical trials, with higher discontinuation rates due to gastrointestinal side effects [4]. The once-weekly injection schedule of Wegovy may offer improved adherence compared to daily oral medications or injections.

Newer dual GIP/GLP-1 receptor agonists have shown even greater weight loss in recent trials, with tirzepatide (Mounjaro) producing up to 22.5% average weight reduction in the SURMOUNT programme [5]. However, Wegovy remains the most extensively studied weight loss medication available through UK pharmacies, with over four years of clinical trial safety data.

Safety Profile and Side Effects in Wegovy Clinical Trials

Understanding the safety profile from wegovy step trial results helps patients prepare for potential side effects. In the STEP trials, gastrointestinal symptoms were the most commonly reported adverse events, affecting approximately 74% of Wegovy participants compared to 48% of placebo recipients [1]. These typically included nausea (44%), diarrhoea (30%), vomiting (24%), and constipation (24%).

Most gastrointestinal side effects occurred during dose escalation and decreased in frequency over time. Only 4.5% of trial participants discontinued Wegovy due to gastrointestinal adverse events, suggesting most patients found these effects manageable [1]. Starting with a low dose and gradually increasing over 16-20 weeks, as per the licensed dosing schedule, minimises side effect severity.

Serious adverse events occurred in 9.8% of Wegovy participants versus 6.4% of placebo recipients, though most were not attributed to the study medication [1]. Gallbladder-related events, including cholelithiasis and cholecystitis, occurred more frequently with Wegovy (2.6%) than placebo (1.2%) [1]. UK prescribers assess your risk factors for gallbladder disease during the clinical consultation before approving treatment.

Cardiovascular Benefits Beyond Weight Loss

The SELECT trial, published in 2023, examined cardiovascular outcomes in over 17,600 adults with established cardiovascular disease and overweight or obesity. Results demonstrated that Wegovy reduced the risk of major adverse cardiovascular events by 20% compared to placebo over a median follow-up of 40 months [6]. This finding led to expanded MHRA licensing for cardiovascular risk reduction in eligible UK patients.

These cardiovascular benefits occurred independently of weight loss, suggesting semaglutide exerts direct protective effects on the heart and blood vessels. At Cured Pharmacy, patients with cardiovascular conditions undergo thorough assessment by our UK clinical team to determine if Wegovy is appropriate for their individual circumstances.

Long-Term Weight Maintenance: Evidence from Extended Wegovy Clinical Trials

One critical question about how much weight can you lose on wegovy concerns long-term sustainability. The STEP 5 trial extended follow-up to 104 weeks (two years), demonstrating that participants maintained an average 15.2% weight reduction at the two-year mark [7]. This extended trial data suggests Wegovy produces durable weight loss when treatment continues alongside lifestyle modifications.

Weight loss plateaus typically occur between weeks 60-68, after which most patients maintain a stable reduced weight with ongoing treatment [7]. This pattern differs from conventional dieting, where weight regain often begins within months of achieving maximum weight loss. The sustained appetite suppression and metabolic effects of semaglutide appear to prevent the compensatory increase in hunger that typically undermines long-term weight maintenance.

However, discontinuation studies show that stopping Wegovy leads to gradual weight regain, with patients recovering approximately 7% of their initial body weight within one year of cessation [3]. This finding emphasises that Wegovy is a long-term treatment rather than a short-term intervention, requiring ongoing commitment and prescriber monitoring.

Starting Wegovy Treatment at Cured Pharmacy: Evidence-Based Weight Loss

At Cured Pharmacy, we provide genuine UK-licensed Wegovy with transparent upfront pricing from £79.00, lower than typical market rates for semaglutide weight loss treatment. Our streamlined online consultation takes under three minutes and is reviewed by UK-registered prescribers who assess your eligibility based on MHRA licensing criteria and clinical guidelines.

Understanding wegovy effectiveness clinical evidence helps set realistic expectations for your weight loss journey. Based on trial data, most patients can expect to lose 10-15% of their starting weight over 12-18 months when combining Wegovy with a reduced-calorie diet and increased physical activity [1][7]. Individual results vary, and your UK prescriber will discuss appropriate goals during your consultation.

All Wegovy prescriptions are dispensed by our GPhC-registered pharmacy (registration number 9012511) with 100% discreet packaging and next-day delivery options. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical services to ensure compliance with UK pharmaceutical regulations. Treatment requires ongoing prescriber monitoring, typically with follow-up assessments every 12 weeks to evaluate response and manage any side effects.

To begin your clinical assessment for Wegovy, complete our online consultation form. A UK prescriber will review your medical history, current medications, and weight loss goals to determine if Wegovy is suitable for you. If approved, your prescription is dispensed and dispatched from our UK pharmacy, typically arriving within 24-48 hours.

Who Can Access Wegovy in the UK

Wegovy is licensed by the MHRA for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea. The medication is also approved for cardiovascular risk reduction in eligible patients following the SELECT trial results [6].

UK prescribers must confirm you meet licensing criteria and have no contraindications before approving treatment. Wegovy is not suitable during pregnancy or breastfeeding, or for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Your online consultation will screen for these and other contraindications to ensure safe prescribing.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
3. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
4. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
6. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563 [accessed 13 August 2026]
7. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Clinical trial results represent average outcomes and individual results may vary. Wegovy should be used alongside a reduced-calorie diet and increased physical activity as part of a comprehensive weight management programme.